- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05137054
재발성/불응성 다발성 골수종 환자를 위한 린볼셀타맙(항 BCMA x 항 CD3 이중특이성 항체) 및 기타 암 치료제(LINKER-MM2)
재발성/불응성 다발성 골수종 환자를 위한 REGN5458(항-BCMA x 항-CD3 이중특이성 항체) 및 기타 암 치료제의 1b상 연구
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.
In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies).
This study is the first time linvoseltamab will be combined with other cancer therapies.
The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination.
The study is looking at several other research questions, including:
- How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma
- What side effects may happen from taking linvoseltamab together with another cancer treatment
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials Administrator
- 전화번호: 844-734-6643
- 이메일: clinicaltrials@regeneron.com
연구 장소
-
-
-
Athens, 그리스, 11528
- 모병
- General Hospital of Athens Alexandra
-
-
Attica
-
Athens, Attica, 그리스, 10676
- 모병
- Evangelismos General Hospital
-
-
-
-
California
-
La Jolla, California, 미국, 92037
- 모병
- Scripps Clinic Torrey Pines
-
-
Georgia
-
Atlanta, Georgia, 미국, 30004
- 모병
- Winship Cancer Institute of Emory University
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Indiana University Health Simon Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana Farber/Harvard Cancer Center
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- 모병
- Karmanos Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic
-
-
New York
-
New York, New York, 미국, 10021
- 모병
- Weill Cornell Medicine/New York Presbyterian Hospital
-
New York, New York, 미국, 10032
- 모병
- New York Presbyterian Hospital Columbia University Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- 모병
- University of North Carolina at Chapel Hill
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Wake Forest University Health Sciences
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- 모병
- The Ohio State University James Cancer Hospital
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern
-
-
Washington
-
Seattle, Washington, 미국, 98108
- 모병
- VA Puget Sound Health Care System
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- Hospital Universitario Vall d'Hebron
-
Barcelona, 스페인, 08036
- 모병
- Hospital Clinic de Barcelona
-
Barcelona, 스페인, 08908
- 모병
- Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
-
Madrid, 스페인, 28050
- 모병
- Hospital Universitario HM Sanchinarro
-
Madrid, 스페인, 28027
- 모병
- Clinica Universidad de Navarra - Madrid
-
Madrid, 스페인, 28006
- 모병
- Universitaru Hospital La Princesa
-
Madrid, 스페인, 28041
- 모병
- University Hospital and Research Institute
-
Madrid, 스페인, 28034
- 모병
- Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
-
Salamanca, 스페인, 37007
- 모병
- University Hospital of Salamanca
-
-
A Coruna
-
Santiago de Compostela, A Coruna, 스페인, 15706
- 모병
- Hospital Clinico Universitario de Santiago
-
-
Barcelona
-
Badalona, Barcelona, 스페인, 08916
- 모병
- Hospital Germans Trias i Pujol
-
-
Cantabria
-
Santander, Cantabria, 스페인, 39008
- 모병
- Hospital Universitario Marques de Valdecilla
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, 스페인, 28223
- 모병
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona, Navarre, 스페인, 31008
- 모병
- Clinica Universidad de Navarra
-
-
-
-
-
Haifa, 이스라엘, 3109601
- 모병
- Rambam Health Care Campus
-
Jerusalem, 이스라엘, 91120
- 모병
- Hadassah Medical Center
-
-
Central District
-
Ramat Gan, Central District, 이스라엘, 5265601
- 모병
- Sheba Medical Center
-
-
-
-
-
Angers, 프랑스, 49933
- 모병
- Centre Hospitalier Universitaire Angers
-
Montpellier, 프랑스, 34295
- 모병
- CHU Montpellier - Departement D'Hematologie
-
Paris, 프랑스, 75571
- 모병
- Saint Antoine Hospital
-
Villejuif, 프랑스, 94805
- 모병
- Institut Gustave Roussy
-
-
New Aquitaine
-
Poitiers, New Aquitaine, 프랑스, 86021
- 모병
- Centre Hospitalier Universitaire (CHU) de Poitiers
-
-
Nord
-
Lille, Nord, 프랑스, 59037
- 모병
- CHU de Lille - Rue Michel Polonovski
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, 프랑스, 44093
- 모병
- Nantes University Hospital
-
-
Île-de-France Region
-
Créteil, Île-de-France Region, 프랑스, 94000
- 모병
- Hospital Henri Mondor
-
Paris, Île-de-France Region, 프랑스, 75015
- 모병
- Hopital Necker
-
Paris, Île-de-France Region, 프랑스, 75010
- 모병
- Saint Louis Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
General Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Participants must have measurable disease as defined in the protocol according to IMWG consensus criteria
- Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol
- Life expectancy of at least 6 months
Cohort Specific Inclusion Criteria:
For cohorts 1-6, each participant must have RRMM with progression following at least 3 lines of therapy, or at least 2 lines of therapy and either prior exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD) and 1 Proteasome Inhibitor (PI), or double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD Cohort 1: Prior treatment with daratumumab is allowed if previously tolerated, as described in the protocol Cohort 2: Prior treatment with carfilzomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 3: Prior treatment with lenalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 4: Prior treatment with bortezomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 5: Prior treatment with pomalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 6: Prior treatment with isatuximab is allowed if previously tolerated, as described in the protocol
Cohort 7 and 8:
- For participants without measurable disease by biochemical parameters [serum or urine M-protein, or serum involved Free Light Chain (FLC)], presence of at least 1 soft tissue plasmacytoma with a single diameter of ≥2 cm
- RRMM with progressive disease and received at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI or triple-class refractory disease (anti-CD38 antibody, IMiD, PI) Cohort 9: Progressive RRMM in participants with triple-class refractory disease (anti-CD38 antibody, IMiD, PI) after at least 3 lines of therapy Cohort 10: Progressive RRMM after at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI
General Key Exclusion Criteria:
- Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (excluding myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
- Participants with known MM brain lesions or meningeal involvement
- Treatment with any systemic anti-myeloma therapy within 5 half-lives or within 21 days prior to first administration of study drug regimen, whichever is shorter
- History of allogeneic and autologous stem cell transplantation, as described in the protocol
- Unless stated otherwise in a specific sub-protocol, prior treatment with a T cell-based immunotherapy directed against B-Cell Maturation Antigen (BCMA) bispecific antibodies and Bispecific T-cell Engagers (BiTEs), and BCMA Chimeric Antigen Receptor (CAR) T cells (Note: BCMA antibody-drug conjugates are not excluded)
- History of progressive multifocal leukoencephalopathy, neurodegenerative condition or Central Nervous System (CNS) movement disorder or participants with a history of seizure within 12 months prior to study enrollment are excluded
- Live or attenuated vaccination within 28 days prior to first study drug regimen administration with a vector that has replicative potential
- Cardiac ejection fraction <40% by Echocardiogram (Echo) or Multigated Acquisition (MUGA) scan
Cohort Specific Exclusion Criteria:
Cohort 2: Dose expansion: Prior treatment with a BCMA-directed CAR T-cell therapy will not be exclusionary if completed at least 12 weeks prior to first study treatment Cohort 3: Known malabsorption syndrome or pre-existing gastrointestinal (GI) condition that may impair absorption of lenalidomide; delivery of lenalidomide via nasogastric tube or gastrostomy tube is not allowed Cohort 4: Peripheral neuropathy grade ≥2 Cohort 5: Known malabsorption syndrome or pre-existing GI conditions that may impair absorption of pomalidomide; delivery of pomalidomide via nasogastric tube or gastrostomy tube is not allowed
Cohort 7:
- Prior treatment with anti-Lymphocyte Activation Gene 3 (LAG-3) agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Programmed cell Death Protein 1 (PD-1) antibodies is permitted, as described in the protocol
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol
- Prior solid organ transplant
- History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies
Cohort 8:
- Prior treatment with anti-PD-1 or anti-PD-L1 agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) antibodies is permitted, as described in the protocol
- Encephalitis or meningitis in the year prior to enrollment
- History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol.
- Prior solid organ transplant
- History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies
Cohort 9:
- Abnormal QT interval corrected by Fridericia's formula (QTcF), as described in the protocol
- Use of concomitant medications that are known to prolong the QT/QTcF interval including Class Ia and Class III antiarrhythmics at the time of informed consent
- Ongoing use or anticipated use of food or drugs that are known strong/moderate cytochrome P450 (CYP)3A4 inhibitors, or strong CYP3A inducers within 14 days prior to first dose of nirogacestat
- Known malabsorption syndrome or existing gastrointestinal GI condition that may impair absorption of nirogacestat; delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed
Cohort 10:
- Known or suspected active Epstein-Barr Virus (EBV) infection
- Known history of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
- Prior treatment with cevostamab or another agent with the same target [Fragment crystallizable Receptor-like 5 (FcRH5)]
Dose finding portion: Prior treatment with any BCMA-directed immunotherapy will not be exclusionary, as described in the protocol Dose expansion portion: Prior treatment with any T cell-engaging bispecific antibody directed against BCMA will be exclusionary, as described in the protocol
NOTE: Other protocol defined inclusion/exclusion criteria apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort 1: Linvoseltamab + Daratumumab
Linvoseltamab + Daratumumab |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 2: Linvoseltamab + Carfilzomib
Linvoseltamab + Carfilzomib |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 3: Linvoseltamab + Lenalidomide
Linvoseltamab + Lenalidomide |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 4: Linvoseltamab + Bortezomib
Linvoseltamab + Bortezomib |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 5: Linvoseltamab + Pomalidomide
Linvoseltamab + Pomalidomide |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 6: Linvoseltamab + Isatuximab
Linvoseltamab + Isatuximab |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 7: Linvoseltamab + Fianlimab
Linvoseltamab + Fianlimab |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 8: Linvoseltamab + Cemiplimab
Linvoseltamab + Cemiplimab |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 9: Linvoseltamab + Nirogacestat
Linvoseltamab + Nirogacestat |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Cohort 10: Linvoseltamab + Cevostamab
Linvoseltamab + Cevostamab |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
심각한 부작용(SAE)의 발생률
기간: 최대 5년
|
최대 5년
|
|
|
TEAE의 심각도
기간: 최대 5년
|
최대 5년
|
|
|
SAE의 심각도
기간: 최대 5년
|
최대 5년
|
|
|
AESI의 심각도
기간: 최대 5년
|
최대 5년
|
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
기간: Up to 5 Years
|
Up to 5 Years
|
|
|
Incidence of Adverse Events of Special Interest (AESIs)
기간: Up to 5 Years
|
Up to 5 Years
|
|
|
Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period
기간: Up to 28 Days
|
Dose finding portion only |
Up to 28 Days
|
|
Incidence of laboratory abnormalities
기간: Up to 5 Years
|
≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v5.0] |
Up to 5 Years
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
전체 생존(OS)
기간: 최대 5년
|
최대 5년
|
|
시간 경과에 따른 혈청 내 총 린보셀타맙의 농도
기간: 최대 5년
|
최대 5년
|
|
Overall Response Rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria
기간: Up to 5 Years
|
Up to 5 Years
|
|
Duration of Response (DOR) by IMWG criteria
기간: Up to 5 Years
|
Up to 5 Years
|
|
Progression-Free Survival (PFS) as measured by IMWG criteria
기간: Up to 5 Years
|
Up to 5 Years
|
|
Rate of Minimal Residual Disease (MRD) negative status by IMWG criteria
기간: Up to 5 Years
|
Up to 5 Years
|
|
Incidence over time of Anti-Drug Antibodies (ADAs) to linvoseltamab
기간: Up to 5 Years
|
Up to 5 Years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Trial Management, Regeneron Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 혈관 질환
- 심혈관 질환
- 신생물
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 림프 증식 장애
- 면역증식성 장애
- 신생물, 형질세포
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 출혈성 장애
- 헴 및 림프병
- 다발성 골수종
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 카르 복실 산
- 파이퍼 리딘
- 무기 화학 물질
- 보 론산
- 산, 비 카르 복실
- 산
- 붕소 화합물
- 피라진
- 프탈리 미드
- 프탈산
- 산, 카르 보 사이 클릭
- 파이퍼리돈
- Isoindoles
- 레날리도마이드
- 보르테조밉
- 카르필 조미 닙
- Pomalidomide
- 다라 토무 맙
- Cemiplimab
- 이사 툭시 맙
- Nirogacestat
기타 연구 ID 번호
- R5458-ONC-2012
- 2020-004638-39 (EudraCT 번호)
- 2023 (미국 NIH 보조금/계약)
- 2023-506247-42-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 공유 기간
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 공유 액세스 기준
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- ANALYTIC_CODE
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .